Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 14/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CD79B | P40259 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26283322 | 1.00 | NT5E (0.76) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23345956 | 1.00 | NT5E (0.76) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23345638 | 0.94 | NT5E (0.76) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23345637 | 0.94 | NT5E (0.76) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL27043403 | 0.94 | NT5E (0.76) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL21839508 | 0.88 | NT5E (0.80) | NT5ECD79B | |
| SCHEMBL22215049 | 0.88 | NT5E (0.80) | NT5ECD79B | |
| SCHEMBL21882835 | 0.88 | NT5E (0.80) | NT5ECD79B | |
| SCHEMBL23345568 | 0.88 | NT5E (0.78) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23345570 | 0.88 | NT5E (0.78) | NT5EADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885 |
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885 |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.